WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Prostate Cancer Efficacy Endpoints_v4, Anatomical region instantiated by -Lung -CNS (brain, leptomeninges) -Bone -Liver -Adrenal (L, R) -Mediastinum (anterior, middle, posterior) -Hilar (L, R) -Plural Fluid, New Lesion identified in Anatomical location, Non-opiate Administration measured at Start Date, Target lesion evaluated by Quantitative assessment, - CR - PR differentiated into Confirmed Response, Time-To-Event end points include Time to initiation of chemotherapy, Sum of longest diameters (SLD) has component LD (axial plane) for target lesion, Functional Status Impairment masured with Functional Status Assessment Tool, OVERALL RESPONSE derived from Sponsor specified Response Criteria (e.g. RECIST), T U M O R R E S P O N S E is assessed with -MRI -CT, -Complete Response (CR) -Non-CR/non-PD -Not evaluated -Not all evaluated -Non-PD -PD -Unequivocal PD -Any summarized into OVERALL RESPONSE, Progression Free Survival (PFS) includes Radiographic Progression Free Survival (rPFS), OVERALL RESPONSE have response options -SD -PD -NE (inevaluable), New lesion identified by Organ specific lesion ID, Non-target lesion evaluated by Qualitative Assessment, Circulating Tumor Cells (CTC) measured in Date, Time to opiate use derived from Opiate Administration, -Complete Response (CR) -Partial Response (PR) -Not all evaluated -Stable disease (SD) -Progressive disease (PD) -Any summarized into OVERALL RESPONSE, Patient Reported Outcomes derived from Functional Status Impairment, LD (axial plane) for target lesion measured in mm